EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Clinical Efficacy of Atorvastatin and PCSK9 Inhibitors in Patients With Borderline Coronary Lesions: An Intravascular Ultrasound Assessment

Zeyu Xu iD, Yi Fang, Yong Peng, Chunhua Zhang, Chunhua Zheng

Journal of Cardiovascular Pharmacology and Therapeutics · 2025

DOI: 10.1177/10742484251361059 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cardiovascular Pharmacology and Therapeutics, 2025. Verfasst von Zeyu Xu und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Third Affiliated Hospital of Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Atorvastatin, Ultrasonography, Interventional, Coronary Artery Disease, Cholesterol, LDL. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Science and Technology Bureau of Nanchang Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While PCSK9 inhibition has proven safe and effective, there is limited research on using intravascular ultrasound (IVUS) to assess the impact of atorvastatin combined with PCSK9 inhibitors on borderline coronary lesions.

Methods

From June 2022 to June 2025, a detailed analysis of biochemical markers, coronary angiography (CAG), and IVUS was conducted on 69 patients with borderline coronary lesions after different treatments.

Results

Of the 69 patients enrolled, 60 completed the 48-week study. All groups showed significant low-density lipoprotein cholesterol (LDL-C) reductions, with Group C (Alirocumab + Atorvastatin) having the largest decrease from 3.64 to 1.48 ( P < .001). At 48 weeks, arterial lumen volumes increased in all groups, but Group C's was significantly larger than Groups A (Alirocumab + placebo) and B (Atorvastatin + placebo) ( P = .038). Group C also had a greater reduction in plaque volume compared to Groups A and B ( P = .041).

Conclusion

Alirocumab and Atorvastatin together significantly lowered LDL-C levels and improved the vascular environment, notably reversing plaque in patients with borderline coronary lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtorvastatinUltrasonography, InterventionalCoronary Artery DiseaseCholesterol, LDLPCSK9 InhibitorsPlaque, AtheroscleroticHydroxymethylglutaryl-CoA Reductase InhibitorsCoronary VesselsHumansMaleFemaleMiddle AgedTreatment OutcomeAgedDrug Therapy, CombinationCoronary AngiographyBiomarkersTime FactorsProprotein Convertase 9

Stichwörter der Autor:innen

IVUSPCSK9 inhibitorsalirocumabatorvastatinborderline coronary lesionscoronary atherosclerosis

Substanzen

AtorvastatinCholesterol, LDLPCSK9 InhibitorsPCSK9 protein, humanHydroxymethylglutaryl-CoA Reductase InhibitorsBiomarkersProprotein Convertase 9

Autor:innen und Institutionen

  • The Third Affiliated Hospital of Nanchang University, Nanchang, China.

ORCID-Profile: Zeyu Xu

Förderung

  • Science and Technology Bureau of Nanchang Municipality

Zitieren

APA

Xu, Z., Fang, Y., Peng, Y., Zhang, C., & Zheng, C. (2025). Clinical Efficacy of Atorvastatin and PCSK9 Inhibitors in Patients With Borderline Coronary Lesions: An Intravascular Ultrasound Assessment. Journal of Cardiovascular Pharmacology and Therapeutics. https://doi.org/10.1177/10742484251361059

Vancouver

Xu Z, Fang Y, Peng Y, Zhang C, Zheng C. Clinical Efficacy of Atorvastatin and PCSK9 Inhibitors in Patients With Borderline Coronary Lesions: An Intravascular Ultrasound Assessment. Journal of Cardiovascular Pharmacology and Therapeutics. 2025. doi:10.1177/10742484251361059

BibTeX
@article{Xu2025,
  author = {Xu, Zeyu and Fang, Yi and Peng, Yong and Zhang, Chunhua and Zheng, Chunhua},
  title = {Clinical Efficacy of Atorvastatin and PCSK9 Inhibitors in Patients With Borderline Coronary Lesions: An Intravascular Ultrasound Assessment},
  journal = {Journal of Cardiovascular Pharmacology and Therapeutics},
  year = {2025},
  doi = {10.1177/10742484251361059}
}
Kostenlos starten →